The global cancer immunotherapy market size reached US$ 106.7 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 182.0 Billion by 2028, exhibiting a growth rate (CAGR) of 8.8% during 2023-2028. The growing number of cancer cases, favorable government initiatives, and wide availability of medical insurance represent some of the key factors driving the market.
Cancer refers to a disease wherein some of the cells in the body grow uncontrollably and spread across several body parts. It is caused by alcohol or tobacco consumption, an unhealthy diet, air pollution, and physical inactivity. It can lead to severe health problems, such as anxiety, depression, fear of death, pain, stress, and suicidal thoughts among individuals. It can be treated through immunotherapy, which comprises antibodies that bind, and inhibit the function of proteins expressed by cancer cells. Cancer immunotherapy assists in boosting the immune system to detect and destroy abnormal cancer cells among individuals. Besides this, it causes fewer side effects as compared to other treatment options and reduces the chances of occurring cancerous cells. As a result, cancer immunotherapy is widely utilized to treat lung, breast, colorectal, melanoma, prostate, head and neck, thyroid, kidney, liver, cervical, bladder, ovarian, and skin cancers among individuals across the globe.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for cancer immunotherapy. Some of the factors driving the North America cancer immunotherapy market included the growing number of patients suffering from cancer, rising development of bioinformatic tools, favorable government initiatives, etc.
Cancer refers to a disease wherein some of the cells in the body grow uncontrollably and spread across several body parts. It is caused by alcohol or tobacco consumption, an unhealthy diet, air pollution, and physical inactivity. It can lead to severe health problems, such as anxiety, depression, fear of death, pain, stress, and suicidal thoughts among individuals. It can be treated through immunotherapy, which comprises antibodies that bind, and inhibit the function of proteins expressed by cancer cells. Cancer immunotherapy assists in boosting the immune system to detect and destroy abnormal cancer cells among individuals. Besides this, it causes fewer side effects as compared to other treatment options and reduces the chances of occurring cancerous cells. As a result, cancer immunotherapy is widely utilized to treat lung, breast, colorectal, melanoma, prostate, head and neck, thyroid, kidney, liver, cervical, bladder, ovarian, and skin cancers among individuals across the globe.
Cancer Immunotherapy Market Trends and Drivers:
At present, the increasing number of cancer cases due to the poor balanced diet and consumption of toxic substances among individuals around the world represents one of the major factors influencing the market positively. In addition, the rising awareness about various cancer treatment options among the masses across the globe is contributing to the market growth. Apart from this, the growing utilization of cancer immunotherapies, as they provide prolonged progression-free survival (PFS) and overall survival (OS) compared to anti-tumor therapies, is offering a positive market outlook. Moreover, the wide availability and easy access to medical insurance, along with the increasing healthcare expenditure, is offering lucrative growth opportunities to industry investors. In addition, there is a rise in the demand for treatment solutions with fewer side effects among the masses around the world. This, coupled with the growing adoption of cancer immunotherapies due to the increasing approval for novel immunotherapies, is bolstering the growth of the market. In line with this, governing agencies and non-profit organizations of various countries are encouraging the adoption of cancer immunotherapy by spreading awareness about cancer prevention worldwide is impelling the growth of the market. Furthermore, various technological advancements in cancer treatment therapies to efficiently treat the disease are strengthening the growth of the market.Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global cancer immunotherapy market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapy type, application and end user.Therapy Type Insights:
- Monoclonal Antibodies
- Cancer Vaccines
- Checkpoint Inhibitors
- Immunomodulators
- Others
Application Insights:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head and Neck Cancer
- Others
End User Insights:
- Hospitals
- Cancer Research Centers
- Clinics
- Others
Regional Insights:
North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global cancer immunotherapy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck KGAA, Novartis AG, Pfizer Inc., Sanofi, Seagen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Regions Covered
North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for cancer immunotherapy. Some of the factors driving the North America cancer immunotherapy market included the growing number of patients suffering from cancer, rising development of bioinformatic tools, favorable government initiatives, etc.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global cancer immunotherapy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck KGAA, Novartis AG, Pfizer Inc., Sanofi, Seagen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report:
- How has the global cancer immunotherapy market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global cancer immunotherapy market?
- What is the impact of each driver, restraint, and opportunity on the global cancer immunotherapy market?
- What are the key regional markets?
- Which countries represent the most attractive cancer immunotherapy market?
- What is the breakup of the market based on the therapy type?
- Which is the most attractive therapy type in the cancer immunotherapy market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the cancer immunotherapy market?
- What is the breakup of the market based on the end user?
- Which is the most attractive end user in the cancer immunotherapy market?
- What is the competitive structure of the global cancer immunotherapy market?
- Who are the key players/companies in the global cancer immunotherapy market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Cancer Immunotherapy Market
6 Market Breakup by Therapy Type
7 Market Breakup by Application
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Amgen Inc.
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck KGAA
- Novartis AG
- Pfizer Inc.
- Sanofi
- Seagen Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | June 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 106.7 Billion |
| Forecasted Market Value ( USD | $ 182 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
